SWOG1826: What are the key takeaways?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Sarah Rutherford, Weill Cornell Medicine, New York, US. We asked, SWOG1826: What are the key takeaways?

Firstly, Rutherford discusses key findings from SWOGS1826 which investigated nivolumab-AVD (N-AVD) versus brentuximab vedotin-AVD (Bv-AVD) in older patients (≥60 years) with advanced Hodgkin lymphoma. She highlights the positive tolerability results for N-AVD therapy compared with Bv-AVD, citing fewer adverse events with N-AVD, such as nausea, diarrhea, and sepsis infections. She then outlines the promising efficacy data, with 93% of patients in the N-AVD arm achieving progression-free survival, compared with 64% in the Bv-AVD arm.

In conclusion, N-AVD has the potential to be a standard-of-care treatment option for older patients with advanced Hodgkin lymphoma; however, further follow-up is warranted.